Supplementary Online Content

Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. *JAMA Oncol.* Published online June 4, 2020. doi:10.1001/jamaoncol.2020.1278

eTable 1. Variables Tested in Cox Proportional Hazards Regression Model for NHL

eTable 2. Baseline Characteristics of NHL Patients Receiving RIC/NMA Conditioning Regimens Followed by allo-HCT

eTable 3. Adjusted Risk of GVHD, NRM, and Progression/Relapse, by Conditioning Regimen

eTable 4. Propensity Score Matching Results

eTable 5. Subset Analysis Results by Conditioning Regimen

eTable 6. Causes of Death

eTable 7. CIBMTR Data Collection Forms

This supplementary material has been provided by the authors to give readers

additional information about their work.

eTable 1. Variables Tested in Cox Proportional Hazards Regression Model for NHL

Main effect:
- Flu/Bu vs. Flu/Cy/2GyTBI vs. Flu/Mel140 vs. Flu/Cy

Patient-related variables:
- Age at transplant: continuous & by age group: decades
- Patient sex: male vs. female
- Karnofsky performance status at transplant: ≥ 90 vs. < 90 vs. missing
- HCT-CI at transplant: 0 vs 1-2 vs ≥ 3 vs. missing
- Race: White vs. others vs. not reported

Disease-related variables:
- Histology: FL vs. DLBCL vs. MCL vs. other B cell vs. T cell
- Remission status at HCT: CR vs PR vs. resistant vs. untreated/unknown vs. missing
- History of autologous transplant: no vs. yes
- Time from diagnosis to HCT: ≥ 12 months vs. < 12 months

Transplant-related variables:
- Transplant donor type: matched related donor vs. matched unrelated donor
- GVHD prophylaxis: CNI + MTX ± others except MMF vs. CNI + MMF ± others vs. CNI + others except MMF, MTX
- ATG/Alemtuzumab use in conditioning: no vs. yes
- Rituximab in conditioning: no vs. yes vs. missing
- Donor-recipient CMV status: -/+ vs. others vs. missing
- Year of transplant: continuous

Abbreviations: ATG, anti-thymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitor; CR, complete remission; Cy, cyclophosphamide; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; Flu, fludarabine; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; MCL, mantle cell lymphoma; Mel, melphalan; MMF, Mycophenolate mofetil; MTX, methotrexate; NHL, non-Hodgkin lymphoma; PR, partial remission; RIC/NMA, reduced-intensity conditioning/non-myeloablative; TBI, total body irradiation.

eTable 2. Baseline Characteristics of NHL Patients Receiving RIC/NMA Conditioning Regimens Followed by alloHCT

	Flu/Bu	Flu/Cy/ 2GyTBI	Flu/Mel140	Flu/Cy	*P* value
Number of patients	458	89	885	391	
Median patient age, years (range)	58 (23-75)	57 (29-74)	20-76)	56 (19-76)	< 0.001
> 60	187 (41)	34 (38)	282 (32)	123 (32)	
Male sex	291 (64)	61 (69)	566 (64)	268 (69)	0.32
Karnofsky performance score ≥ 90	260 (57)	58 (65)	549 (62)	265 (68)	< 0.001
Not reported	2 (<1)	4 (4)	20 (2)	24 (6)	
HCT-CI					< 0.001
0	107 (23)	46 (52)	323 (36)	143 (37)	
1-2	142 (31)	20 (22)	246 (28)	112 (29)	
≥ 3	207 (45)	19 (21)	293 (33)	98 (25)	
Not reported	2 (<1)	4 (4)	23 (3)	38 (10)	
Patient race					< 0.001
White	429 (94)	80 (90)	736 (83)	329 (84)	
Other	29 (6)	9 (10)	145 (16)	61 (16)	
Not reported	0	0	4 (<1)	1 (<1)	
Donor type					0.003
Matched related donor	219 (48)	45 (51)	456 (52)	236 (60)	
Matched unrelated donor	239 (52)	44 (49)	429 (48)	155 (40)	
Lymphoma subtype					< 0.001
Follicular lymphoma	95 (21)	32 (36)	152 (17)	138 (35)	
Diffuse large B-cell lymphoma	151 (33)	17 (19)	296 (33)	78 (20)	
Mantle cell lymphoma	81 (18)	15 (17)	132 (15)	116 (30)	
Other B-cell lymphoma	20 (4)	9 (10)	44 (5)	19 (5)	
T-cell NHL	111 (24)	16 (18)	261 (29)	40 (10)	
Remission at HCT					0.09
Complete remission	202 (44)	50 (56)	364 (41)	162 (41)	
Partial remission	190 (41)	33 (37)	379 (43)	162 (41)	
Resistant	53 (12)	6 (7)	125 (14)	57 (15)	
Untreated/Not reported	13 (3)	0	17 (2)	10 (3)	
History of prior autoHCT	179 (39)	32 (36)	326 (37)	133 (34)	0.5
Median time from diagnosis to HCT, months (range)	33 (3-340)	46 (3-236)	29 (<2-460)	38 (2-310)	0.001
GVHD prophylaxis					0.001
CNI + MMF +- other(s)	117 (26)	23 (26)	100 (11)	68 (17)	
CNI + MTX +- other(s)	307 (67)	61 (69)	494 (56)	249 (64)	
CNI + other(s)	34 (7)	5 (6)	291 (33)	74 (19)	
ATG/alemtuzumab in conditioning	159 (35)	47 (53)	269 (30)	81 (21)	0.001
Rituximab use in conditioning	7 (2)	35 (39)	80 (9)	199 (51)	0.001
CMV status = Donor negative/ Recipient positive	113 (25)	15 (17)	222 (25)	88 (23)	0.04
Year of HCT					
2008-2010	120 (26)	45 (51)	216 (24)	166 (42)	
2011-2013	168 (37)	35 (39)	320 (36)	144 (37)	

2014-2016	170 (37)	9 (10)	349 (39)	81 (21)	
Median follow-up of survivors, months (range)	48 (3-101)	71 (9-103)	47 (2-117)	60 (3-115)	

Abbreviations: allo, allogeneic; auto, autologous; ATG, anti-thymocyte globulin; Bu, busulfan; CNI, calcineurin inhibitor; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; Mel, melphalan; MMF, Mycophenolate mofetil; MTX, methotrexate; NHL, non-Hodgkin lymphoma; RIC/NMA, reduced-intensity conditioning/non-myeloablative; TBI, total body irradiation.

eTable 1. Adjusted Risk of GVHD, NRM, and Progression/Relapse, by Conditioning Regimen

	N	OR (95% CI)	*P* value	*Q* value
Grade 3-4 acute GVHD [a]				
Flu/Bu	432	1	**0.15** [b]	
Flu/Cy/2GyTBI	78	0.81 (0.37-1.77)	0.59	1
Flu/Mel140	832	1.42 (0.99-2.02)	0.05	0.74
Flu/Cy	378	1.34 (0.9-2.01)	0.15	0.74
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.57 (0.27-1.22)	0.15	0.74
Flu/Cy/2GyTBI vs Flu/Cy		0.60 (0.27-1.32)	0.21	0.77
Flu/Mel140 vs Flu/Cy		1.06 (0.75-1.49)	0.76	1.00
Chronic GVHD [c]	**N**	**HR (95% CI)**	***P* value**	***Q* value**
Flu/Bu	437	1	**0.006** [b]	
Flu/Cy/2GyTBI	84	0.96 (0.68-1.34)	0.79	1
Flu/Mel140	827	1.12 (0.94-1.33)	0.21	1
Flu/Cy	377	0.81(0.67-0.99)	0.04	0.29
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.85 (0.61-1.19)	0.35	1
Flu/Cy/2GyTBI vs Flu/Cy		1.18 (0.83-1.67)	0.35	1
Flu/Mel140 vs Flu/Cy		1.38 (1.15-1.65)	< 0.001	0.006
Non-relapse mortality [d]	**N**	**HR (95% CI)**	***P* value**	***Q* value**
Flu/Bu	457	1	**< 0.001** [b]	
Flu/Cy/2GyTBI	89	0.75 (0.43-1.31)	0.31	0.97
Flu/Mel140	879	1.78 (1.37-2.31)	< 0.001	< 0.001
Flu/Cy	389	1.00 (0.7-1.42)	0.99	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.42 (0.25-0.72)	0.001	0.005
Flu/Cy/2GyTBI vs Flu/Cy		0.75 (0.42-1.34)	0.33	0.97
Flu/Mel140 vs Flu/Cy		1.79 (1.33-2.39)	< 0.001	< 0.001
Progression/relapse [e]	**N**	**HR (95% CI)**	***P* value**	***Q* value**
Flu/Bu	458	1	**0.001** [b]	
Flu/Cy/2GyTBI	89	0.65 (0.44-0.97)	0.04	0.15
Flu/Mel140	885	0.79 (0.66-0.94)	0.007	0.07
Flu/Cy	391	1.08 (0.88-1.33)	0.48	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.83 (0.56-1.23)	0.36	1
Flu/Cy/2GyTBI vs Flu/Cy		0.61 (0.40-0.91)	0.02	0.10
Flu/Mel140 vs Flu/Cy		0.73 (0.60-0.88)	0.001	0.01
Progression-free survival [f]	**N**	**HR (95% CI)**	***P* value**	***Q* value**
Flu/Bu	458	1	**0.09** [b]	
Flu/Cy/2GyTBI	89	0.70 (0.51-0.98)	0.04	0.2
Flu/Mel140	885	1.03 (0.89-1.19)	0.71	1
Flu/Cy	391	1.07 (0.89-1.29)	0.46	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.68 (0.50-0.94)	0.02	0.15
Flu/Cy/2GyTBI vs Flu/Cy		0.66 (0.47-0.91)	0.01	0.15
Flu/Mel140 vs Flu/Cy		0.96 (0.81-1.13)	0.61	1

(continued on next page)

Overall Survival [g]		HR (95% CI)		
Flu/Bu	458	1	**< 0.001** [b]	
Flu/Cy/2GyTBI	89	0.72 (0.49-1.06)	0.10	0.37
Flu/Mel140	885	1.34 (1.13-1.59)	< 0.001	< 0.001
Flu/Cy	391	0.88 (0.7-1.11)	0.27	0.79
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.54 (0.37-0.78)	0.001	0.0049
Flu/Cy/2GyTBI vs Flu/Cy		0.82 (0.55-1.23)	0.33	0.81
Flu/Mel140 vs Flu/Cy		1.53 (1.25-1.87)	< 0.001	< 0.001

Abbreviations: Bu, Busulfan; CI, confidence interval; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HR, hazard ratio; Mel, Melphalan; TBI, total body irradiation.

[a] Grade 3-4 acute GHVD adjusted for GVHD prophylaxis.

[b] Overall P values show whether the main effect was significant based on the Wald test in the final model. The other P values are from pairwise comparisons between two conditioning regimens. For each outcome, the first 3 P values show the P values from pairwise comparisons against the reference group (Flu/Bu). The 3 P values in the contrast are from the pairwise comparisons as stated. All pairwise comparisons were from the Wald test.

[c] Chronic GVHD adjusted for donor type, GVHD prophylaxis, ATG/alemtuzumab use in conditioning.

[d] NRM adjusted for age, KPS, HCT-CI, prior autoHCT, and ATG/alemtuzumab use in conditioning.

[e] Progression/relapse adjusted for remission at HCT, NHL subtype, donor type, ATG/alemtuzumab use in conditioning.

[f] Progression free survival adjusted for KPS, NHL subtype, remission at HCT, ATG/alemtuzumab use in conditioning.

[g] Overall survival adjusted for patient age, KPS, HCT-CI, NHL subtype, remission status at HCT, and ATG/alemtuzumab use in conditioning.

eTable 4. Propensity Score Matching Results

	N	HR (95% CI)	*P* value	*Q* value
Non-relapse mortality				
Conditioning regimen [a]				
Flu/Bu	415	1	< 0.001 [b]	
Flu/Cy/2GyTBI	88	0.75 (0.42-1.35)	0.35	1
Flu/ Mel140	587	1.91 (1.48-2.46)	< 0.001	< 0.001
Flu/Cy	376	1.02 (0.73-1.42)	0.90	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.40 (0.23-0.68)	< 0.001	0.004
Flu/Cy/2GyTBI vs Flu/Cy		0.74 (0.40-1.37)	0.34	1
Flu/Mel140 vs Flu/Cy		1.87 (1.42-2.46)	< 0.001	< 0.001
Progression/relapse [c]				
Conditioning regimen [d]				
Flu/Bu	415	1	0.003 [b]	
Flu/Cy/2GyTBI	88	0.66 (0.42-1.03)	0.07	0.26
Flu/ Mel140	587	0.82 (0.69-0.97)	0.02	0.15
Flu/Cy	376	1.09 (0.87-1.37)	0.45	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.81 (0.52-1.24)	0.33	0.97
Flu/Cy/2GyTBI vs Flu/Cy		0.60 (0.39-0.94)	0.03	0.15
Flu/Mel140 vs Flu/Cy		0.75 (0.62-0.91)	0.003	0.04
Progression-free survival [e]				
Conditioning regimen [f]				
Flu/Bu	415	1	0.06 [b]	
Flu/Cy/2GyTBI	88	0.68 (0.48-0.97)	0.03	0.15
Flu/ Mel140	587	1.07 (0.93-1.24)	0.35	1
Flu/Cy	376	1.05 (0.89-1.25)	0.55	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.63 (0.45-0.89)	0.01	0.15
Flu/Cy/2GyTBI vs Flu/Cy		0.64 (0.45-0.93)	0.02	0.15
Flu/Mel140 vs Flu/Cy		1.02 (0.86-1.99)	0.85	1
Overall survival [g]				
Conditioning regimen [h]				
Flu/Bu	416	1	< 0.001 [b]	
Flu/Cy/2GyTBI	88	0.79 (0.52-1.18)	0.25	0.92
Flu/ Mel140	587	1.43 (1.20-1.71)	< 0.001	< 0.001
Flu/Cy	376	0.90 (0.72-1.13)	0.36	1
Contrast				
Flu/Cy/2GyTBI vs Flu/Mel140		0.55 (0.37-0.81)	0.003	0.014
Flu/Cy/2GyTBI vs Flu/Cy		0.87 (0.58-1.31)	0.51	1
Flu/Mel140 vs Flu/Cy		1.59 (1.29-1.95)	< 0.001	< 0.001

Abbreviations: Bu, Busulfan; CI, confidence interval; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HR, hazard ratio; Mel, Melphalan; TBI, total body irradiation

[a] Non-relapse mortality adjusted for significant covariates: patient age, KPS, HCT-CI, prior autoHCT, ATG/alemtuzumab use in conditioning

[b] Overall *P* values showing whether the main effect was significant based on the Wald test in the final model. The other *P* values are from pairwise comparisons between two conditioning regimens. For each outcome, the first 3 *P* values show the *P* values from pairwise comparisons against the reference group (Flu/Bu). The 3 *P* values in the contrast are from the pairwise comparisons as stated. All pairwise comparisons were from the Wald test.

[c] Progression/relapse adjusted for significant covariates: remission status at HCT, NHL histology, donor type, ATG/alemtuzumab use in conditioning

[d] Non-relapse mortality adjusted for significant covariates: patient age, KPS, HCT-CI, prior autoHCT, ATG/alemtuzumab use in conditioning

[e] Progression free survival adjusted for significant covariates: KPS, NHL histology, remission status at HCT, ATG/alemtuzumab use in conditioning

[f] Non-relapse mortality adjusted for significant covariates: patient age, KPS, HCT-CI, prior autoHCT, ATG/alemtuzumab use in conditioning

[g] Overall survival adjusted for significant covariates: patient age, KPS, HCT-CI, NHL histology, remission status at HCT, ATG/alemtuzumab use in conditioning

[h] Non-relapse mortality adjusted for significant covariates: patient age, KPS, HCT-CI, prior autoHCT, ATG/alemtuzumab use in conditioning.

eTable 5. Subset Analysis Results by Conditioning Regimen

	N	HR	HR Lower CI	HR Upper CI	*P* value
Non-relapse mortality[a]					
Flu/Bu	415	1			
Flu/Mel140	587	1.88	1.47	2.41	<0.001
Progression/relapse[b]					
Flu/Bu	415	1			
Flu/Mel140	587	0.82	0.69	0.97	0.02
Progression-free survival[c]					
Flu/Bu	415	1			
Flu/Mel140	587	1.07	0.93	1.24	0.34
Overall survival[d]					
Flu/Bu	416	1			
Flu/Mel140	587	1.42	1.19	1.69	<0.001

Note: The *P* values are from a pairwise comparison between Flu/Bu and Flu/Mel140 based on the Wald test.

[a] Non-relapse mortality adjusted for significant covariates: patient age, KPS, HCT-CI, prior autoHCT, ATG/alemtuzumab use in conditioning
[b] Progression/relapse adjusted for significant covariates: remission status at HCT, NHL histology, donor type, ATG/alemtuzumab use in conditioning
[c] Progression-free survival adjusted for significant covariates: KPS, NHL histology, remission status at HCT, ATG/alemtuzumab use in conditioning
[d] Overall survival adjusted for significant covariates: patient age, KPS, HCT-CI, NHL histology, remission status at HCT, ATG/alemtuzumab use in conditioning.

eTable 6. Causes of Death

	Flu/Bu	Flu/Cy/2GyTBI	Flu/Mel140	Flu/Cy
Number of patients	**194**	**30**	**428**	**143**
Cause of death, No. (%)				
Primary disease	103 (53)	11 (37)	164 (38)	60 (42)
Graft-versus-host disease	28 (14)	6 (20)	46 (11)	13 (9)
Infection	22 (11)	3 (10)	73 (17)	18 (13)
Organ failure	11 (6)	3 (10)	47 (11)	19 (13)
Secondary malignancy	4 (2)	1 (3)	12 (3)	4 (3)
Graft failure	3 (2)	1 (3)	31 (7)	2 (1)
IPS/ARDS	2 (1)	0	2 (<1)	3 (2)
Organ toxicity	0	0	1 (<1)	0
Vascular	0	0	5 (1)	2 (1)
Other causes [a]	16 (8)	3 (10)	35 (8)	18 (13)
Unknown	5 (3)	2 (7)	12 (3)	4 (3)

Abbreviations**:** IPn, idiopathic pneumonia syndrome; ARDS, acute respiratory distress syndrome

[a] Other causes: **Flu/Bu**: 14 other HCT-related cause, not otherwise specified (NOS); 1 colon perforation; 1 sudden death. **Flu/Cy/2GyTBI:** 3 other HCT-related cause, NOS. **Flu/Mel140:** 29 other HCT-related cause, NOS; 1 accidental death; 1 complication from gallbladder surgery; 1 suicide; 1 large volume hemoptysis following NGT placement; 1 respiratory distress not related to HCT; 1 sudden death. **Flu/Cy:** 15 other HCT-related cause, NOS; 1 accidental overdose; 1 broken femur; 1 motor vehicle accident.

eTable 7. CIBMTR Data Collection Forms

Form	Revision	Link
Pre-Transplant Essential Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2402/Rev4.0/2402R4.pdf
Pre-Transplant Essential Data	5	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2400/Rev5.0/2400R5.0.pdf
Pre-Transplant Essential Data	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2400/Rev4.0/2400R4.0.pdf
Pre-Transplant Essential Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Pages/DataCollectionFormInfo.aspx?dcfid=357
Pre-Transplant Essential Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2400/Rev2.0/Pre-TED-080409-r2.pdf
Pre-Transplant Essential Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2400/Rev1.0/Pre-TED-1.pdf
Pre-Transplant Disease Classification	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2402/Rev4.0/2402R4+.pdf
Pre-Transplant Disease Classification	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2400/Rev1.0/Pre-TED-1.pdf
Pre-Transplant Disease Classification	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2402/Rev2.0/2402R2.0.pdf
Pre-Transplant Disease Classification	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2402/Rev1.0/2402R1.0.pdf
Post-Transplant Essential Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2450/Rev5.0/2450R5+.pdf
Post-Transplant Essential Data	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2450/Rev4.0/2450R4.0.pdf
Post-Transplant Essential Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2450/Rev3.0/2450R3.0.pdf
Post-Transplant Essential Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2450/Rev2.0/Post-TED-081009-r2x.pdf
Post-Transplant Essential Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2450/Rev1.0/Post-TED-1.pdf
Confirmation of HLA Typing	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev7.0/2005R7.pdf
Confirmation of HLA Typing	6	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev6.0/2005R6.0.pdf
Confirmation of HLA Typing	5	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev5.0/2005R5.0.pdf
Confirmation of HLA Typing	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev4.0/Form2005_R4_Retired.pdf
Confirmation of HLA Typing	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev3.0/combine-2005_HLA_r3_.pdf
Confirmation of HLA Typing	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev2.0/combine-2005-HLA-r2.pdf
Confirmation of HLA Typing	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2005/Rev1.0/combine_2005_HLA.pdf
Infectious disease markers	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2004/Rev5.0/2004R5+.pdf
Infectious disease markers	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2004/Rev4.0/2004R4.0.pdf

Infectious disease markers	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2004/Rev3.0/Form2004_R3_Retired.pdf
Infectious disease markers	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2004/Rev2.0/combine-2004-IDMs-r2.pdf
Infectious disease markers	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2004/Rev1.0/combine_2004_IDMs.pdf
Hematopoietic Cellular Transplant Infusion	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2006/Rev5.0/2006R5+.pdf
Hematopoietic Cellular Transplant Infusion	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2006/Rev4.0/2006R4.0.pdf
Hematopoietic Cellular Transplant Infusion	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2006/REV3.0/Form2006_R3_Retired.pdf
Hematopoietic Cellular Transplant Infusion	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2006/Rev2.0/combine-2006-INF-r2.pdf
Hematopoietic Cellular Transplant Infusion	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2006/Rev1.0/combine_2006_INF.pdf
Recipient Baseline Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2000/Rev5.0/2000R5.pdf
Recipient Baseline Data	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2000/Rev4.0/2000R4.0+.pdf
Recipient Baseline Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2000/Rev3.0/Form2000_R3_Retired.pdf
Recipient Baseline Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2000/Rev2.0/2000-Baseline-r2-rtrd.pdf
Recipient Baseline Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2000/Rev1.0/combine_2000_baselin.pdf
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2018/Rev5/2018R5.pdf
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2018/Rev4.0/2018R4.0.pdf
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2018/Rev3.0/2018.R3.0.pdf
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2018/Rev2.0/Form2018_R2_Retired.pdf
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2018/Rev1.0/combine_2018_LYM_201.pdf
Post-HCT Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2100/Rev5.0/2100R5.0.pdf
Post-HCT Data	4	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2100/Rev4.0/2100R4.0.pdf
Post-HCT Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2100/Rev3.0/2100R3.0.pdf
Post-HCT Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2100/Rev2.0/combine-2100-Follow-.pdf

Post-HCT Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2100/Rev1.0/combine_2100_Follow_.pdf
Hodgkin and Non-Hodgkin Lymphoma Post-Infusion Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2118/Rev4.0/2118R4.0.pdf
Hodgkin and Non-Hodgkin Lymphoma Post-Infusion Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2118/Rev3.0/2118R3.0.pdf
Hodgkin and Non-Hodgkin Lymphoma Post-Infusion Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2118/Rev2.0/Form2118_R2_Retired.pdf
Hodgkin and Non-Hodgkin Lymphoma Post-Infusion Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2118/Rev1.0/combine_2118_LYM.pdf
Recipient Death Data	Active	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2900/Rev4/2900R4.pdf
Recipient Death Data	3	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2900/Rev3.0/2900R3.0.pdf
Recipient Death Data	2	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2900/Rev2.0/Form%202900%20R2%20(8).pdf
Recipient Death Data	1	https://www.cibmtr.org/DataManagement/DataCollection Forms/Documents/2900/Rev1.0/combine_2900_Death.pdf